PTCA199-3: Vitamin C to Chemotherapy Related Anemia in Pancreatic Cancer
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the efficacy of low-dose vitamin C on improving the quality of life for metastatic pancreatic cancer patients receiving gemcitabine and nab-paclitaxel chemotherapy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
Pancreatic cancer is a highly lethal malignancy with a 5-year survival less than 10%. Approximately 80% of patients with pancreatic cancer are diagnosed at an advanced stage. Chemotherapy is one of the major treatments for advanced pancreatic cancer. The Metastatic PAncreatic Cancer Trial (MPACT) has confirmed the efficacy of gemcitabine combined with nab-paclitaxel as the first-line treatment to metastatic pancreatic cancer. However, the side-effects related to gemcitabine combined with nab-paclitaxel including anemia, hand/foot numbness, fatigue, nausea, and malnutrition have impaired the tolerability of the regimen.
Vitamin C, also called ascorbate, is an essential nutrient for the human body. It modulates metabolism, immune reaction, collagen synthesis, and iron absorption. Some studies have shown that high-dose intravenous Vitamin C may be effective against various types of cancer. Meanwhile, medium or low dose of Vitamin C may enhance the tolerability of chemotherapy by increasing iron absorption, improving anemia, alleviating pain and hand/foot numbness, and thus improving quality of life for patients with pancreatic cancer.
The purpose of this study is to evaluate the efficacy of low-dose vitamin C on improving the quality of life for metastatic pancreatic cancer patients receiving gemcitabine and nab-paclitaxel chemotherapy. One hundred patients will be randomly assigned to the experimental group (gemcitabine combined with nab-paclitaxel, Vitamin C) or the control group (gemcitabine combined with nab-paclitaxel). Rate of anemia, rate of hand/foot numbness, severity of pain, quality of life, and overall survival are measured every four weeks.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Ascorbate nab-paclitaxel (120 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks. Vitamin C 900 mg/day, three times a day, orally. |
Drug: Ascorbate
Vitamin C 900 mg/day, three times a day, orally.
Other Names:
Drug: Nab paclitaxel
Nab-paclitaxel (120 mg per square meter of body-surface area) on days 1, 8, and 15 every 4 weeks
Other Names:
Drug: Gemcitabine
Gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks
Other Names:
|
| Other: Control nab-paclitaxel (120 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks. |
Drug: Nab paclitaxel
Nab-paclitaxel (120 mg per square meter of body-surface area) on days 1, 8, and 15 every 4 weeks
Other Names:
Drug: Gemcitabine
Gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Rate of anemia [At the end of Cycle 1 (each cycle is 28 days)]
Rate of anemia after every cycle of chemotherapy
Secondary Outcome Measures
- Rate of hand-foot skin reaction (HFSR) [At the end of Cycle 1 (each cycle is 28 days)]
Rate of HFSR after every cycle of chemotherapy
- Change of numeric rating scale (NRS) [At the end of Cycle 1 (each cycle is 28 days)]
Change of NRS and the administration of analgesic drugs after every cycle of chemotherapy. The range of NRS scale is 0-10 and higher scores mean a worse outcome.
- Quality of life (QOL) [At the end of Cycle 1 (each cycle is 28 days)]
Change of QOL after every cycle of chemotherapy assessed using European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
- Overall survival (OS) [At the end of Cycle 1 (each cycle is 28 days)]
OS of subjects from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Ability to understand and the willingness to sign a written informed consent document.
-
Age ≥ 18 years and ≤ 80 years.
-
Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
-
Histologically or cytologically confirmed metastatic pancreas adenocarcinoma.
-
Adequate organ performance based on laboratory blood tests.
-
Presence of at least of one measurable lesion in agreement to Response Evaluation Criteria in Solid Tumours (RECIST) criteria.
-
Hemoglobin (Hgb) ≥ 8 g/dL.
-
The expected survival ≥ 3 months.
-
Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation.
Exclusion Criteria:
-
Patients who have received any form of anti-tumor therapy.
-
The diagnosis was confirmed by pathology as non-adenocarcinoma of pancreas.
-
Inflammation of the digestive tract, including pancreatitis, cholecystitis, cholangitis, etc.
-
Pregnant or nursing women.
-
Glucose-6-phosphate dehydrogenase (G6PD) deficiency.
-
Severe and uncontrollable accompanying diseases that may affect protocol compliance or interfere with the interpretation of results, including active opportunistic infections or advanced (severe) infections, and diabetes that cannot be controlled after adequate clinical anti-hyperglycemia treatment according to guidelines, uncontrollable hypertension, cardiovascular disease (Class III or IV heart failure as defined by the New York Heart Association classification, congestive heart failure (CHF), myocardial infarction in the past 6 months , unstable arrhythmia or unstable angina, cerebral infarction within 3 months, etc).
-
Renal insufficiency or dialysis
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine, nab-paclitaxel, or other agents used in the study.
-
Other serious accompanying illnesses, which, in the researcher's opinion, could seriously adversely affect the safety of the treatment.
-
Patients who are unwilling or unable to comply with study procedures.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Shanghai Cancer Center | Shanghai | Shanghai | China | 200032 |
Sponsors and Collaborators
- Fudan University
Investigators
- Principal Investigator: Guopei Luo, MD, Fudan University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PTCA199-3